AMGN vs REGN
AMGN and REGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | AMGNAmgen Inc. | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $251.64B | — |
| P/E (TTM) | 28.9 | 21.3 |
| P/B | 21.53 | — |
| P/S | 6.8x | — |
| Dividend yield | 2.04% | — |
| Revenue | $38.09B(TTM) | $16.90B(TTM) |
| Revenue growth (YoY) | 10.0% | 1.0% |
| Net income | $8.74B(TTM) | $4.82B(TTM) |
| Earnings growth (YoY) | 88.5% | 2.1% |
| EPS, diluted | $16.10(TTM) | $45.24(TTM) |
| EBIT margin | 24.7% | 24.9% |
| ROE | 66.0% | 13.4% |
| ROIC | 15.1% | 9.2% |
| 1y total return | +58.2% | +47.6% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: AMGN frente a REGN
| Métrica | AMGN | REGN |
|---|---|---|
| Valor final | $41.5K | $27.8K |
| Retorno total | +314.6% | +177.8% |
| CAGR | +14.7% | +10.4% |
| Volatilidad | 25.1% | 32.3% |
| Sharpe | 0.51 | 0.34 |
| Sortino | 0.75 | 0.50 |
| Caída máxima | -24.9% | -59.7% |
Basado en 2600 días de negociación comunes, 2016-06-30 → 2026-11-02 · tasa libre de riesgo 4.21% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)